Steroids, Surgery, and Biologics, Oh My! Following the Path to Selecting Appropriate Treatments for Individual Patients with CRSwNP – Pretest

1. What is your degree?

2. What is your specialty?

3. How confident are you in the management of patients with CRSwNP in your practice?

4. CRSwNP is most frequently manifested in patients with which inflammatory endotype?

5. Which are the key primary cytokines involved in the pathophysiology of Type 2 inflammatory endotype?

6. Although to different extents, which primary endpoint did clinical trials for all 3 of the biologics approved for CRSwNP meet?

7. According to the EUFOREA criteria is the following patient a candidate for biologic therapy?
49-year-old female with bilateral nasal polyps with previous FESS. Shows evidence of T2 inflammation and has had 2 courses of OCS in the past year.

8. According to the EUFOREA criteria is the following patient a candidate for biologic therapy?
55-year-old male with bilateral nasal polyps and comorbid asthma. Has no previous history of surgery. Shows evidence of T2 inflammation and reports loss of smell and impaired QOL related to polyps.

9. After 6 months of using a biologic for his nasal polyps, a 52-year-old CRSwNP patient shows no improvement in any of the symptom assessment scores advocated by EUFOREA guidelines. What should you do at this point, according to the guidelines?